GB201900530D0 - Bicyclic peptide ligands specific for CD38 - Google Patents

Bicyclic peptide ligands specific for CD38

Info

Publication number
GB201900530D0
GB201900530D0 GBGB1900530.5A GB201900530A GB201900530D0 GB 201900530 D0 GB201900530 D0 GB 201900530D0 GB 201900530 A GB201900530 A GB 201900530A GB 201900530 D0 GB201900530 D0 GB 201900530D0
Authority
GB
United Kingdom
Prior art keywords
peptide ligands
ligands specific
bicyclic peptide
bicyclic
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900530.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleRD Ltd
Original Assignee
BicycleRD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleRD Ltd filed Critical BicycleRD Ltd
Priority to GBGB1900530.5A priority Critical patent/GB201900530D0/en
Publication of GB201900530D0 publication Critical patent/GB201900530D0/en
Priority to US17/422,943 priority patent/US20220133733A1/en
Priority to JP2021541187A priority patent/JP2022517399A/ja
Priority to EP20701838.3A priority patent/EP3911366A1/en
Priority to CN202080021078.5A priority patent/CN113597317A/zh
Priority to PCT/GB2020/050074 priority patent/WO2020148530A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1900530.5A 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38 Ceased GB201900530D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1900530.5A GB201900530D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38
US17/422,943 US20220133733A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38
JP2021541187A JP2022517399A (ja) 2019-01-15 2020-01-15 Cd38に特異的な二環式ペプチドリガンド
EP20701838.3A EP3911366A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38
CN202080021078.5A CN113597317A (zh) 2019-01-15 2020-01-15 Cd38特异性的双环肽配体
PCT/GB2020/050074 WO2020148530A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900530.5A GB201900530D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38

Publications (1)

Publication Number Publication Date
GB201900530D0 true GB201900530D0 (en) 2019-03-06

Family

ID=65528178

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900530.5A Ceased GB201900530D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38

Country Status (6)

Country Link
US (1) US20220133733A1 (cg-RX-API-DMAC10.html)
EP (1) EP3911366A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022517399A (cg-RX-API-DMAC10.html)
CN (1) CN113597317A (cg-RX-API-DMAC10.html)
GB (1) GB201900530D0 (cg-RX-API-DMAC10.html)
WO (1) WO2020148530A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN118388598A (zh) * 2024-04-22 2024-07-26 苏州大学附属第一医院 标记前体、探针及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050091716A (ko) * 2002-12-12 2005-09-15 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. 글리코겐 신타제 키나제-3 억제제
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
PT3149025T (pt) * 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
JP2018521960A (ja) * 2015-04-28 2018-08-09 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) 酵素で活性化された第XII因子(FXIIa)の新規阻害剤
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38

Also Published As

Publication number Publication date
US20220133733A1 (en) 2022-05-05
CN113597317A (zh) 2021-11-02
EP3911366A1 (en) 2021-11-24
JP2022517399A (ja) 2022-03-08
WO2020148530A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
GB201900529D0 (en) Bicyclic peptide ligands specific for CD38
IL290089A (en) Heterotandem bicyclic peptide complexes
IL287881A (en) Ox40-specific bicyclic peptide ligands
PT4464721T (pt) Complexos peptídicos bicíclicos heterotandem
GB201900525D0 (en) Bicyclic peptide ligands specific for caix
GB201900526D0 (en) Bicyclic peptide ligands specific for caix
GB201820325D0 (en) Bicyclic peptide ligands specific for psma
GB201810320D0 (en) Peptide ligands for binding to CD38
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201800593D0 (en) Bicyclic peptide ligands specific for CD38
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201800610D0 (en) Bicylic peptide ligands specific for CD38
GB201918488D0 (en) Bicyclic peptide ligands specific for chymase
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918558D0 (en) Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) Bicyclic peptide ligands specific for IL-17
GB201701834D0 (en) Bicyclic peptide ligands specific for CD38
GB201918497D0 (en) Bicyclic peptide ligands specific for klk7
GB201905631D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904621D0 (en) Bicyclic peptide ligands specific for PD-L1
GB201904622D0 (en) Bicyclic peptide ligands specific for pd-l1

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)